Surovatamig not checked

AstraZeneca · AZD0486 · TNB-486

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
11 active
11 in total · 8 in the EU
Targets
 

What this is

How it works
An antibody built to latch onto two or more targets at once.-mig: multi-specific immunoglobulins WHO name stem
How it’s given
“Fully human bispecific monoclonal immunoglobulins (Ig) G4 antibody”In the company’s words, NCT07911553 on ClinicalTrials.gov
Tested for
Large B-cell Lymphoma (3 trials), B-cell Non-Hodgkin Lymphoma (3 trials), Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV, Untreated Follicular Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL), Primary Membranous Nephropathy, B-cell Acute Lymphoblastic Leukemia (B-ALL) and 9 more
Main trialPhase 3
“The purpose of this study is to measure the efficacy and safety of R-mini-CHOP × 2 followed by AZD0486 compared with R-mini-CHOP × 6 in elderly or unfit participants newly diagnosed with LBCL.”In the company’s words, NCT07215585 on ClinicalTrials.gov
Other names
AZD0486 · TNB-486

Other drugs for Large B-cell Lymphoma

All 86 drugs for Large B-cell Lymphoma

Coming up11

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials11

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 10 Jun 2030 AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL
Phase 3Not yet recruiting 2 Sep 2030 A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80 Years of Age With Previously Untreated Large B-cell Lymphoma With IPI Score 2 to 5
Phase 3Recruiting 29 Aug 2031 Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
Phase 3Recruiting 26 Nov 2031 A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
Phase 2Recruiting 21 Apr 2028 Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Phase 2Recruiting 13 Oct 2028 A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease
Phase 1/2Recruiting 6 Jan 2028 AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Phase 1/2Recruiting 4 Jul 2028 A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Phase 1/2Recruiting 20 May 2030 A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Phase 1Active, not recruiting 19 Jun 2028 A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
Phase 1Recruiting 27 Jun 2028 Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Surovatamig

Following is part of Solo: you see every change to Surovatamig the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in